Research confirms benefits of side-actuated nasal spray
Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.
The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.
The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.
Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.
The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.
You may also like
Pharmaceutical
![CellCarta adds Tempus to companion diagnostic commercialisation network]()
CellCarta adds Tempus to companion diagnostic commercialisation network
Read moreCellCarta has partnered with Tempus to expand its CDx Commercialization Lab Network, giving biopharma sponsors a route from companion diagnostic development and regulatory approval to commercial testing in US oncology practice
Trending Articles
You may also like
Pharmaceutical
![CellCarta adds Tempus to companion diagnostic commercialisation network]()
CellCarta adds Tempus to companion diagnostic commercialisation network
CellCarta has partnered with Tempus to expand its CDx Commercialization Lab Network, giving biopharma sponsors a route from companion diagnostic development and regulatory approval to commercial testing in US oncology practice
Drug Delivery
![SCHOTT Pharma expands portfolio for sensitive biologics with cartriQ BioPure]()
SCHOTT Pharma expands portfolio for sensitive biologics with cartriQ BioPure
The new high‑performance sterile glass cartridge is engineered for stability of complex biologics across their shelf life. It complements EVERIC pure vials and syriQ BioPure syringes, enabling an unbiased container choice across the drug lifecycle. Commercial launch is planned for year‑end at CPHI Milan 2026; samples are already available
Manufacturing
![SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs]()
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
